Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to, inter alia, the CNS applied via intranasal administration while reducing non-target exposure are provided. In certain embodiments, at least one vasoconstrictor is provided intranasally prior to intranasal administration of at least one therapeutic compound. In other embodiments, the vasoconstrictor(s) and therapeutic compound(s) are combined in a pharmaceutical composition and delivered intranasally. The present invention substantially increases targeting of the therapeutic compound(s) to, inter alia, the CNS while substantially reducing unwanted and potentially harmful systemic exposure. The preferred administration of the invention applies the vasoconstrictor(s) and/or therapeutic compound(s) to the upper third of the nasal cavity, though application to the lower two-thirds of the nasal cavity is also within the scope of the invention.
1. A method for treating a patient with Parkinson's disease, with increased targeting efficiency for at least one delivery target related to anatomical structures located in the rostral portion of the patient's brain compared to any delivery targets in the caudal portion of the patient's brain, and increased delivery of deferoxamine thereto compared with the caudal portion of the patient's brain, comprising:
providing at least an effective amount of deferoxamine;
providing at least an effective amount of at least one vasoconstrictor; administering the at least an effective amount of deferoxamine to the upper third of the patient's nasal cavity;
administering the at least an effective amount of the at least one vasoconstrictor to the upper third of the patient's nasal cavity; thereby increasing targeting efficiency of the administered amounts of deferoxamine to the patient's olfactory epithelium and thereby enabling at least an effective amount of deferoxamine to bypass the patient's blood-brain barrier;
delivering an effective amount of deferoxamine to at least one target in the rostral portion of the patient's brain, with increased efficiency as compared with the delivery efficiency of deferoxamine within the caudal portion of the patient's brain;
minimizing the amount of deferoxamine absorbed into the patient's blood and/or peripheral tissues; and
treating the patient's Parkinson's Disease.
2. The method of claim 1 , wherein the at least one vasoconstrictor comprises phenylephrine and/or tetrahydrozoline.
3. A method for treating a patient with Parkinson's disease, with increased targeting efficiency for at least one delivery target related to anatomical structures located in the rostral portion of the patient's brain compared to any delivery targets in the caudal portion of the patient's brain, and increased delivery of insulin thereto compared with the caudal portion of the patient's brain, comprising:
providing at least an effective amount of insulin;
providing at least an effective amount of at least one vasoconstrictor; administering the at least an effective amount of insulin to the upper third of the patient's nasal cavity; administering the at least an effective amount of the at least one vasoconstrictor to the upper third of the patient's nasal cavity; thereby increasing targeting efficiency of the administered amounts of insulin to the patient's olfactory epithelium and thereby enabling at least an effective amount of insulin to bypass the patient's blood-brain barrier;
delivering an effective amount of insulin to at least one target in the rostral portion of the patient's brain, with increased efficiency as compared with the delivery efficiency of insulin within the caudal portion of the patient's brain;
minimizing the amount of insulin absorbed into the patient's blood and/or peripheral tissues; and
treating the patient's Parkinson's disease.
4. The method of claim 3 , wherein the at least one vasoconstrictor comprises phenylephrine and/or tetrahydrozoline.
5. A method for treating a patient with Parkinson's Disease, with increased targeting efficiency for at least one delivery target related to anatomical structures located in the rostral portion of the patient's brain compared to any delivery targets in the caudal portion of the patient's brain, and increased delivery of a composition comprising deferoxamine and insulin thereto compared with the caudal portion of the patient's brain, comprising:
providing at least an effective amount of the composition comprising deferoxamine and insulin;
providing at least an effective amount of at least one vasoconstrictor; administering the at least an effective amount of the composition comprising deferoxamine and insulin to the upper third of the patient's nasal cavity; administering the at least an effective amount of the at least one vasoconstrictor to the upper third of the patient's nasal cavity; thereby increasing targeting efficiency of the administered amounts of the composition comprising deferoxamine and insulin to the patient's olfactory epithelium and thereby enabling at least an effective amount of the composition comprising deferoxamine and insulin to bypass the patient's blood-brain barrier;
delivering an effective amount of deferoxamine and insulin to at least one target in the rostral portion of the patient's brain, with increased efficiency as compared with the delivery efficiency of deferoxamine and insulin within the caudal portion of the patient's brain;
minimizing the amount of deferoxamine and insulin absorbed into the patient's blood and/or peripheral tissues; and
treating the patient's Parkinson's disease.
6. The method of claim 5 , wherein the at least one vasoconstrictor comprises phenylephrine and/or tetrahydrozoline.